Prospective randomized comparison of effect on coronary endothelial and renal function between febuxostat and benzbromarone in hyperuricemic patients with coronary artery disease: EFEF study
Abstract Background and Aims There are two types of serum uric acid‐lowering agents, the xanthine oxidoreductase (XO) inhibitor and non‐XO inhibitor. We investigated whether febuxostat, XO inhibitor, could produce more favorable effects on coronary endothelial function (CEF) and renal function than...
Main Authors: | Masami Nishino, Yasuyuki Egami, Hitoshi Nakamura, Kohei Ukita, Akito Kawamura, Yutaka Matsuhiro, Koji Yasumoto, Masaki Tsuda, Akihiro Tanaka, Naotaka Okamoto, Yasuharu Matsunaga‐Lee, Masamichi Yano, Ryu Shutta, Jun Tanouchi |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-03-01
|
Series: | Health Science Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/hsr2.563 |
Similar Items
-
A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
by: Fengchun Zhang, et al.
Published: (2019-09-01) -
A rare case of thrombocytopenia secondary to taking febuxostat
by: Isabella Di Zio, et al.
Published: (2024-04-01) -
Astragaloside IV improves the pharmacokinetics of febuxostat in rats with hyperuricemic nephropathy by regulating urea metabolism in gut microbiota
by: Zhen Xiong Zhao, et al.
Published: (2022-12-01) -
Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
by: Shengzhao Zhang, et al.
Published: (2021-06-01) -
Celebrating Versatility: Febuxostat’s Multifaceted Therapeutic Application
by: Krasimir Iliev Kraev, et al.
Published: (2023-11-01)